These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 29069471

  • 1. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
    Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, Ravaud P, Sibilia J, Pane I, Mariette X, Gottenberg JE, French Society of Rheumatology.
    Rheumatology (Oxford); 2018 Jan 01; 57(1):134-139. PubMed ID: 29069471
    [Abstract] [Full Text] [Related]

  • 2. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
    Grøn KL, Arkema EV, Glintborg B, Mehnert F, Østergaard M, Dreyer L, Nørgaard M, Krogh NS, Askling J, Hetland ML, ARTIS Study Group.
    Ann Rheum Dis; 2019 Mar 01; 78(3):320-327. PubMed ID: 30612115
    [Abstract] [Full Text] [Related]

  • 3. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
    Grøn KL, Glintborg B, Nørgaard M, Mehnert F, Østergaard M, Dreyer L, Krogh NS, Hetland ML.
    Rheumatology (Oxford); 2020 Aug 01; 59(8):1949-1956. PubMed ID: 31764977
    [Abstract] [Full Text] [Related]

  • 4. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.
    Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, Houvenagel E, Gaudin P, Loeuille D, Rist S, Dougados M, Sibilia J, Le Loët X, Meyer O, Solau-Gervais E, Marcelli C, Bardin T, Pane I, Baron G, Perrodeau E, Mariette X, all the investigators of the ORA registry and the French Society of Rheumatology.
    Ann Rheum Dis; 2016 Jun 01; 75(6):1108-13. PubMed ID: 26048170
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X, French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.
    BMJ; 2019 Jan 24; 364():l67. PubMed ID: 30679233
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov 24; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Int J Rheum Dis; 2016 Nov 24; 19(11):1103-1111. PubMed ID: 26692536
    [Abstract] [Full Text] [Related]

  • 8. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.
    Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, Combe B, Gottenberg JE, Schaeverbeke T, Soubrier M, Vittecoq O, Dougados M, Saraux A, Mariette X, Ravaud P, Sibilia J.
    Rheumatology (Oxford); 2017 Oct 01; 56(10):1746-1754. PubMed ID: 28957557
    [Abstract] [Full Text] [Related]

  • 9. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    JAMA Intern Med; 2017 Nov 01; 177(11):1605-1612. PubMed ID: 28975211
    [Abstract] [Full Text] [Related]

  • 10. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.
    Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, Houvenagel E, Gaudin P, Loeuille D, Rist S, Dougados M, Sibilia J, Le Loët X, Marcelli C, Bardin T, Pane I, Baron G, Mariette X.
    Ann Rheum Dis; 2012 Nov 01; 71(11):1815-9. PubMed ID: 22615458
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.
    Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Mariette X, Gottenberg JE, French Society of Rheumatology.
    Rheumatology (Oxford); 2016 May 01; 55(5):874-82. PubMed ID: 26822072
    [Abstract] [Full Text] [Related]

  • 12. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
    Mariette X, Gottenberg JE, Ravaud P, Combe B.
    Rheumatology (Oxford); 2011 Jan 01; 50(1):222-9. PubMed ID: 21148156
    [Abstract] [Full Text] [Related]

  • 13. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
    Tarp S, Eric Furst D, Boers M, Luta G, Bliddal H, Tarp U, Heller Asmussen K, Brock B, Dossing A, Schjødt Jørgensen T, Thirstrup S, Christensen R.
    Rheumatology (Oxford); 2017 Mar 01; 56(3):417-425. PubMed ID: 28013201
    [Abstract] [Full Text] [Related]

  • 14. Safety profile of biological therapies for treating rheumatoid arthritis.
    Cañete JD, Hernández MV, Sanmartí R.
    Expert Opin Biol Ther; 2017 Sep 01; 17(9):1089-1103. PubMed ID: 28657381
    [Abstract] [Full Text] [Related]

  • 15. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Gorla R, Bazzani C, Govoni M, Farina I, Gremese E, Carletto A, Giollo A, Galeazzi M, Foti R, Bianchino L, La Grasta L, Lapadula G.
    Clin Rheumatol; 2018 Feb 01; 37(2):315-321. PubMed ID: 28980085
    [Abstract] [Full Text] [Related]

  • 16. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept.
    Rempenault C, Lukas C, Combe B, Herrero A, Pane I, Schaeverbeke T, Wendling D, Pham T, Gottenberg JE, Mariette X, Morel J, French Society of Rheumatology and the investigators participating in AIR-PR, ORA and REGATE registries.
    Rheumatology (Oxford); 2022 Mar 02; 61(3):953-962. PubMed ID: 33993216
    [Abstract] [Full Text] [Related]

  • 17. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d'Elia H, Askling J, ARTIS Study group.
    Ann Rheum Dis; 2018 May 02; 77(5):650-657. PubMed ID: 29237621
    [Abstract] [Full Text] [Related]

  • 18. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
    Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S.
    Semin Arthritis Rheum; 2018 Dec 02; 48(3):399-405. PubMed ID: 29673963
    [Abstract] [Full Text] [Related]

  • 19. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
    Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A, Listing J.
    Ann Rheum Dis; 2017 Mar 02; 76(3):504-510. PubMed ID: 27405509
    [Abstract] [Full Text] [Related]

  • 20. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
    Provan SA, Berg IJ, Hammer HB, Mathiessen A, Kvien TK, Semb AG.
    PLoS One; 2015 Mar 02; 10(6):e0130709. PubMed ID: 26114946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.